Neurological
Refine Search
Pharmaceutical
US drugmaker AbbVie was trading more than 11% lower early on Monday afternoon in New York. 11 November 2024
Pharmaceutical
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research.. 11 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Pharmaceutical
In what was a busy couple of days for the Anglo-Swedish drug major, AstraZeneca (LSE: AZN), through its US subsidiary MedImmune, has entered into an agreement with privately-held Immune Design Corp for the use and commercialization of IDC's proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases. 26 October 2010
Pharmaceutical
US drugmaker Cephalon (Nasdaq: CEPH) says that it has exercised its option to acquire spinal treatment specialist BioAssets Development Corp (BDC), following receipt of interim data from a Phase II placebo-controlled proof-of-concept study evaluating epidural administration of a tumor necrosis factor (TNF) inhibitor for the treatment of sciatica in 45 patients. 25 October 2010
Pharmaceutical
Over the next decade, the epilepsy drug market will remain relatively flat, increasing from $2.8 billion in 2009 to $2.9 billion in 2019 in the USA, France, Germany, Italy, Spain, UK and Japan, according to advisory firm Decision Resources. 25 October 2010
Pharmaceutical
The European Commission has granted clearance under the EU Merger Regulation to the creation of a joint venture between DocMorris NV and K-Mail Order GmbH & Co KG. The joint venture will operate an internet and mail order pharmacy, with activities mainly in Germany. 22 October 2010
Biotechnology
US biotech major Genzyme Nasdaq: GEN), which is fending off an unsolicited takeover bid from France's Sanofi-Aventis (Euronext; SAN), has presented positive clinical trials data for its currently marketed chronic lymphocytic leukemia drug Campath (alemtuzumab) in the treatment of multiple sclerosis. 18 October 2010
Pharmaceutical
French drug major Sanofi-Aventis (Euronext: SAN) announced positive results from the two year Phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS), which met its goals, including delayed disability progression. The data were presented during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress, in Gothenburg, Sweden last Friday. 18 October 2010
Generics
US drugmaker Mylan (Nasdaq: MYL) has received final approvals from the US Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for the generic versions of drug giant Merck & Co (NYSE: MRK) antihypertensives Hyzaar (losartan, potassium and hydrochlorothiazide) 50mg/12.5 mg and 100mg/25mg tablets, and Cozaar (losartan potassium) 25mg, 50mg and 100mg. 18 October 2010
Pharmaceutical
The US Food and Drug Administration on Friday approved Allergan's (NYSE: AGN) Botox injection (onabotulinumtoxinA), better known as an anti-wrinkle product, to prevent headaches in adult patients with chronic migraine. Reacting to the news, Allergan's stock rose 6.6% to $73.40 at 6:42pm in extended New York trading. 18 October 2010
Pharmaceutical
Labopharm (TSX: DDS) and fellow Canada-headquartered Paladin Labs (TSX: PLB) have expanded their commercial relationship through three licensing and distribution agreements under which Paladin will distribute two of Labopharm's products in certain jurisdictions. 15 October 2010
Pharmaceutical
Supported by funding from the Wellcome Trust, researchers at the University of Edinburgh, Scotland, have identified a new experimental compound that can improve memory and cognitive function in aging mice. The compound is being investigated with a view to developing a drug that could slow the natural decline in memory associated with aging, and the scientists hope to take into human trials within a year. 15 October 2010
Pharmaceutical
Global pharmaceuticals behemoth Pfizer (NYSE: PFE), which is still digesting its mega $68 billion buy of Wyeth last year, has now set its sights on a smaller target, the fellow USA-based specialty drugmaker King Pharmaceuticals (NYSE: KG), in a deal valuing the later at $3.6 billion, or $14.25 a share, in cash, a 40% premium to its closing price the previous day and 46% average over the past month. King's shares leapt 39% to $14.14 on the news yesterday morning. 13 October 2010
Pharmaceutical
In what is clearly a boost to the developmental stage Swiss firm, Belgian drugmaker UCB (UCB: BB) is making an equity investment of $20 million in Basel-based Synosia Therapeutic as part of a Series C funding in Synosia. 13 October 2010
Pharmaceutical
Danish drugmaker Lundbeck A/S (LUND: DC) announced a worldwide commercialization agreement with US drugs giant Merck & Co (NYSE: MRK) for the latter's antipsychotic drug Sycrest (asenapine) sublingual tablets (5mg, 10mg). 13 October 2010
Pharmaceutical
The US Food and Drug Administration has approved drugmaker Alkermes' (Nasdaq: ALKS) alcohol dependence drug Vivitrol (naltrexone) for the treatment and prevention of relapse after patients with opioid dependence have undergone detoxification treatment. 13 October 2010
Biotechnology
Less than two months after the US government lifted its clinical hold on such research, Geron Corp (Nasdaq: GERN) has announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. 13 October 2010
Pharmaceutical
Two bits of negative news came out of the US Food and Drug Administration that will delay the approvals of drug candidates currently under review by the agency, one submitted by Jazz Pharmaceuticals (Nasdaq: JAZZ) and the other by Valeant Pharmaceuticals (NYSE: VRX) partner Alexza Pharmaceuticals (Nasdaq: ALXA). 12 October 2010
Pharmaceutical
Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning said it has received a positive agreement for approval in 23 countries across the European Union for Vimovo naproxen/esomeprazole magnesium). It also results in a harmonized Summary of Product Characteristics (SmPC). EU member states will now pursue pricing and reimbursement and national approvals. 11 October 2010
Pharmaceutical
US health care major Abbott Laboratories (NYSE: ABT) has agreed to voluntarily withdraw its obesity drug Meridia (sibutramine) from the US market because of clinical trial data indicating an increased risk of heart attack and stroke, the Food and Drug Administration announced last Friday. 11 October 2010
Pharmaceutical
Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502) has formed a three-year research alliance Envoy Therapeutics, a recently-formed US drug discovery company, aimed at discovering drugs for schizophrenia that will have greater efficacy and safety compared to current therapies. 11 October 2010
Pharmaceutical
Targacept (Nasdaq: TRGT) saw its share fall 5% in pre-market trading yesterday, when the firm revealed that top-line results from a Phase II clinical trial of AZD1446 conducted by Anglo-Swedish drug major AstraZeneca (LSE: AZN) in adults with attention-deficit hyperactivity disorder (ADHD) were disappointing and would likely see the drug dropped for this indication. 8 October 2010
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze